No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration of a combined oral contraceptive (COC) containing norgestimate/ethinylestradiol has not been studied. Based on metabolism and clearance a clinically significant interaction with emtricitabine is unlikely. No clinically significant drug interactions were observed when tenofovir-DF was coadministered with a combined oral contraceptive (COC) containing ethinylestradiol/norgestimate (norgestimate AUC and Cmax decreased by 4% and 5%; ethinylestradiol AUC, Cmax and Cmin decreased by 4%, 6% and 2%, respectively).
Coadministration of norgestimate/ethinylestradiol was studied with tenofovir disoproxil fumarate. Norgestimate AUC and Cmax decreased by 4% and 5%; ethinyl oestradiol AUC, Cmax and Cmin decreased by 4%, 6% and 2%, respectively. No dose adjustment of norgestimate/ethinyl estradiol is required.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
No clinically significant drug interactions have been observed between TDF and oral contraceptives.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking